Establishment Labs Holdings Inc

Establishment Labs Holdings, Inc. is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It generates income from customers in Europe, the Middle East, Latin America, and Asia. The firm's products include Motiva Implants, Motiva Flora Tissue Expander, Motiva Ergonomix, and Motiva Ergonomix2. The company was founded by Juan Jose Chacon-Quiros in 2004 and is headquartered in Alajuela, Costa Rica.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Establishment Labs posts strong revenue growth and sets ambitious targets

Establishment Labs reported strong revenue growth in Q4 2022 and outlined ambitious revenue guidance for 2023, supported by strategic product launches and market expansion initiatives.
While facing challenges in managing expenses and optimizing margins, the company's focus on growth opportunities and market transformation positions it for long-term success and achieving its revenue targets.
With a solid cash position, investments in new facilities, and a clear roadmap for future growth, Establishment Labs demonstrates resilience and strategic foresight in navigating the competitive landscape.

Establishment Labs (ESTA) reports robust Q1 revenue growth and global expansion

Establishment Labs Holdings Inc (ESTA) delivered strong revenue growth and strategic advancements in Q1 2023, positioning the company for future success.
While facing challenges in managing expenses and entering new markets, the company's focus on innovation and global expansion presents promising opportunities.
With a solid financial foundation and a clear growth strategy, ESTA is poised to capitalize on market demand and drive sustainable growth in the coming quarters.

Establishment Labs Holdings Inc reports strong Q2 growth and eyes expansion in China and Europe

Establishment Labs Holdings Inc's Q2 2023 performance showcased revenue growth and strategic advancements, despite challenges in profitability margins.
The company's focus on expanding into new markets, launching innovative products, and strengthening partnerships presents promising growth opportunities.
Maintaining revenue guidance, preparing for new launches, and addressing operational challenges position the company for a strong finish to 2023.

Establishment Labs maintains revenue amid global slowdown, eyes future growth

Establishment Labs faces challenges from a global slowdown in aesthetics procedures but sees opportunities in new markets and innovative products.
The company's focus on cost control and cash preservation aligns with expectations of positive EBITDA and cash flow in the future.
Key strengths include FDA clearances, positive study outcomes, and confidence in growth prospects beyond 2023.

Establishment Labs (ESTA) reports robust Q4 revenue and eyes global expansion

Establishment Labs Holdings Inc (ESTA) demonstrated strong revenue growth and cost management in Q4 2023.
The company faces challenges in gross profit and cash utilization but is poised for improved margins and profitability in 2024 and beyond.
Opportunities lie in global expansion, market penetration with innovative products, and a focus on achieving positive cash flow in the near future.

Establishment Labs reports strong Q1 revenue and eyes global growth

Establishment Labs Holdings Inc showed strong Q1 performance with revenue of $37.2 million.
The company aims to achieve positive adjusted EBITDA by end of 2024 and positive cash flow by end of 2025.
Progress in FDA approvals, market diversification, and strategic expansion plans are key strengths.
Challenges include addressing net losses, achieving positive EBITDA, and upcoming FDA inspection.

Establishment Labs Holdings Inc reports strong Q2 performance and eyes U.S. and China growth

Establishment Labs Holdings Inc demonstrated strong revenue growth and progress towards profitability in Q2 2024.
While facing challenges in Latin America, the company is capitalizing on opportunities in the U.S. and China markets.
With a focus on new product launches and improving gross margins, the company is poised for future growth and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the events and activities planned for the month of October in support of Pink October and Breast Cancer Awareness Month. “One in eight women will experience breast cancer in her lifetime. While survival rates have improved, the disease can still have a

Establishment Labs Announces Events for Pink October and Breast Cancer Awareness Month

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, held a symposium at the London Breast Meeting on Thursday, September 2, 2021, marking the official launch of the company's Motiva Flora® tissue expander in Europe and other CE Mark countries. The symposium's moderator Professor Jian Farhadi, Chair of the London Breast

Establishment Labs Launches Motiva Flora Tissue Expander in Europe and Other CE Mark Countries

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it will host an event on September 2, 2021 marking the official launch of the company's Motiva Flora® tissue expander in Europe and other CE Mark countries. Motiva Flora offers several notable advances, including Establishment Labs' patented SmoothSilk®

Establishment Labs to Launch Motiva Flora Tissue Expander at London Breast Meeting on September 2, 2021

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Presentation time in the release dated August 2, 2021, should read 8:00 am PT on Thursday, August 12, 2021 (instead of 8 am ET). The updated release reads: ESTABLISHMENT LABS ANNOUNCES PARTICIPATION IN THE UBS GENOMICS 2.0 AND MEDTECH INNOVATIONS SUMMIT Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced

CORRECTING and REPLACING Establishment Labs Announces Participation in the UBS Genomics 2.0 and MedTech Innovations Summit

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Interim Chief Financial Officer and Head of Strategy and Investor Relations, will participate in the UBS Genomics 2.0 and MedTech Innovations Summit, which is being held

Establishment Labs Announces Participation in the UBS Genomics 2.0 and MedTech Innovations Summit

Establishment Labs Holdings, Inc. (ESTA) CEO Juan José Chacón Quirós on Q2 2021 Results - Earnings Call Transcript

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the second quarter ended June 30, 2021 and provided updated 2021 guidance. Second Quarter Highlights and Outlook Second quarter worldwide sales of $32.0 million, an increase of 205% year-over-year and a new quarterly record; re

Establishment Labs Reports Record Second Quarter 2021 Financial Results and Raises Full Year Guidance

On Thursday, July 29, Establishment Labs Hldgs (NASDAQ:ESTA) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Earnings Preview: Establishment Labs Hldgs

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced publication of its 2020 Corporate Social Responsibility annual review to coincide with the third anniversary of the company's public listing on NASDAQ. “As a publicly traded company, we are already subject to the highest standards of governance and compliance, but we are taki

Establishment Labs Releases 2020 Corporate Social Responsibility Annual Review

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended June 30, 2021, before the market opens on Thursday, July 29, 2021, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (2

Establishment Labs to Announce Second Quarter 2021 Financial Results on July 29

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced the appointment of Ann Custin and Bryan Slotkin to its Board of Directors, effective immediately. “We are delighted to have these two very accomplished individuals join the Board of Establishment Labs,” said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. “Goo

Establishment Labs Announces Appointment of Ann Custin and Bryan Slotkin to Board of Directors

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that Renee Gaeta will step down from her position as Chief Financial Officer for another opportunity outside of the company, effective July 30, 2021 and following the planned release of the company's second quarter financial results. Raj Denhoy, Head of Strategy and Investor

Establishment Labs Announces Departure of CFO and Appointment of Raj Denhoy as Interim CFO

Establishment Labs Holdings Inc. (ESTA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Here's What Could Help Establishment Labs Holdings Inc. (ESTA) Maintain Its Recent Price Strength

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today held the groundbreaking ceremony for its new SulayIöm Innovation Campus in Costa Rica. When complete, the new facilities will total approximately 145,000 square feet (13,500 square meters) and will support the company's continued global growth with additional capacity and capabilities

Establishment Labs Breaks Ground on Third Facility, Preparing to Expand Capabilities in Manufacturing, R&D, and Medical Education

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced results from a landmark study investigating how different breast implant surfaces affect the host immune response. The purpose of the study was to determine the optimal breast implant surface topography that induces the least amount of adverse foreign-body response and unders

Establishment Labs Announces Publication of Landmark Breast Implant Surface Research in Nature Biomedical Engineering

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, announced today that Heather Brennan has joined the company as Head of U.S. Commercial Operations and Neeta Toprani has joined as General Counsel & Corporate Secretary. “As we prepare for commercialization in the United States and China and the significant scaling of our business, the ad

Establishment Labs Announces Appointments of Heather Brennan as Head of U.S. Commercial Operations and Neeta Toprani as General Counsel & Corporate Secretary

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the Jefferies Virtual Healthcare Conference, which is being held June 1-4, 2021. Mr. Chacón-Quirós and Mrs. Gaeta are scheduled to speak to conference attendees at 2:00 pm

Establishment Labs Announces Participation in the Jefferies Virtual Healthcare Conference

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, announced today that Pratip Dastidar has been appointed Head of Global Operations. Mr. Dastidar will join the executive team at Establishment Labs with responsibility for operational transformation and the scaling of global operations; he will also lead the company's digital transformation i

Establishment Labs Announces Pratip Dastidar Has Joined the Company as Head of Global Operations

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the UBS Global Healthcare Virtual Conference, which is being held May 24-26, 2021. Mr. Chacón-Quirós and Mrs. Gaeta are scheduled to speak to conference attendees at 9:00

Establishment Labs Announces Participation in the UBS Global Healthcare Virtual Conference

Establishment Labs Holdings, Inc. (ESTA) CEO Juan José Chacón Quirós on Q1 2021 Results - Earnings Call Transcript

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced its financial results for the first quarter ended March 31, 2021 and provided updated 2021 guidance. First Quarter Highlights and Outlook First quarter worldwide sales of $30.3 million, an increase of 24% year-over-year and a new quarterly record. 2021 guidance increased to a

Establishment Labs Reports Record First Quarter 2021 Financial Results and Raises Full Year Guidance

Establishment Labs Holdings Inc. (ESTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Establishment Labs Holdings Inc. (ESTA) Report Negative Earnings Next Week? What You Should Know

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced it has completed enrollment in its one hundred patient Motiva Mia® case series in Costa Rica. The Institutional Review Board (IRB) approved study began in December 2020 and follows the initial 2019 case series in Asia. Establishment Labs also announced that is has submitted t

Establishment Labs Completes Enrollment of One Hundred Patient Motiva Mia IRB Study

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended March 31, 2021 before the market opens on Wednesday, May 5, 2021, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8039 (U.S. and Canada) or (20

Establishment Labs to Announce First Quarter 2021 Financial Results on May 5

Establishment Labs Holdings, Inc. (ESTA) CEO Juan José Chacón Quirós on Q4 2020 Results - Earnings Call Transcript

News for Establishment Labs Holdings Inc Stock (ESTA)